Is RGEN stock a Buy, Sell, or Hold?

Based on our analysis, RGEN is currently a HOLD with low confidence. 📊 HOLD: RGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of RGEN stock?

Our analysis estimates the fair value range for RGEN to be between $160.21 and $169.12. The current price is $149.37.

What is the analyst price target for RGEN?

The average Wall Street analyst price target for RGEN is $190.89. This implies a potential upside of 22.1% from current levels.

RGEN Stock Analysis: Buy, Sell, or Hold?

RGEN - Repligen Corp

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

$149.37

-7.00 (-4.48%) ▼

HOLD

LOW Confidence

Protect Your RGEN Gains

Last Updated: January 30, 2026

Earnings: Feb 19, 2026 18d

Get Alerted When RGEN Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: RGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 24.4%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$99.76

Based on 14.2% avg growth

INTRINSIC VALUE TODAY

$61.94

Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: RGEN is currently trading at $149.37, which is considered oversold relative to its 30-day fair value range of $160.21 to $169.12. The stock's valuation (Forward PE: 75.4) is in line with its historical norms (78.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This pessimistic expectation contrasts with the company's recent 160.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, RGEN is in a strong uptrend. The price is currently testing key support at $151.70. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $190.89 (+22.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Fair Price Range $160.21 - $169.12

Company Quality Score 58/100 (HOLD)

Options IV Signal 50th percentile (NORMAL)

Volume Confirmation HIGH

Confidence Score 73.8%

Protect Your Profits

Holding RGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Options fairly priced (IV 50th percentile)
NEUTRAL: Mixed technical signals (40/100)
BULLISH: High volume confirmation
BEARISH: Downward momentum (-4.5%)
BULLISH: Trading 22.1% below Wall St target ($190.89)
CAUTION: Recommendation downgraded due to -8.0% 5-day decline

Fair Price Analysis

30-Day Fair Range $160.21 - $169.12

Current vs Fair Value OVERSOLD

Expected Move (7 Days) ±$9.60 (6.4%)

Support & Resistance Levels

Support Level $151.70

Resistance Level $174.87

Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 75.36

Wall Street Target $190.89 (+22.1%)

Revenue Growth (YoY) 21.9%

Earnings Growth (YoY) 160.0%

Profit Margin 0.2%

Valuation Discount vs History -1.3% cheaper

PE vs Historical 75.4 vs 78.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -1.3% (market-implied from PE analysis)

1-Year Target $154.34 (-1%)

2-Year Target $152.33 (-3%)

3-Year Target $150.35 (-4%)

3-Yr Target (if PE normalizes) (PE: 75→78) $156.42 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 75.4, Growth: 24.4%) $301.04 (+93%)

Base: (SPY PE: 22.3, Growth: 24.4%) $89.08 (-43%)

Bear: (PE: 19.0, Growth: 24.4%) $75.72 (-52%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (88x PE), but valuation improves significantly next year (75x PE) as earnings recover.

Forward PE: 87.72 | Forward EPS (Implied): $1.70

Bull Case $180.36 (+21%)

Analyst growth 15.0%, PE expands to 92.1

Base Case $149.37 (0%)

Market implied 0.0%, PE stable at 87.7

Bear Case $114.27 (-24%)

Severe decline -15.0%, PE contracts to 79.0

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 75.4 to 78.4

Stabilization Target: $162.68 (+4.0%)

PE Expansion Potential: +4.0%

Last updated: January 30, 2026 10:05 PM ET
Data refreshes hourly during market hours. Next update: 11:05 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is RGEN showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS BUYING

Recent Transactions

Martin D Madaus BUY 1800 shares 2025-08-08

View Insider Activity Scanner

Top Rated Medical Instruments & Supplies Stocks

Top-rated stocks in Medical Instruments & Supplies by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
ALC Alcon AG	STRONG BUY 27 analysts	$92	63 BUY
ISRG Intuitive Surgical Inc	BUY 33 analysts	$608	58 HOLD
RMD ResMed Inc	BUY 19 analysts	$292	57 HOLD
ALGN Align Technology Inc	BUY 18 analysts	$184	62 BUY
COO The Cooper Companies, Inc	BUY 19 analysts	$91	58 HOLD

ALC Alcon AG

63 BUY

ISRG Intuitive Surgica…

58 HOLD

RMD ResMed Inc

57 HOLD

ALGN Align Technology …

62 BUY

COO The Cooper Compan…

58 HOLD

Advanced RGEN Option Strategies

Professional options setups generated by AI based on today's RGEN price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for RGEN

RGEN Technical Chart RGEN Price Prediction RGEN Earnings Date RGEN Investment Advisor RGEN Fair Price Analyzer RGEN Options Advisor RGEN Options Chain RGEN Options Analysis RGEN Competitors

Compare RGEN with Other Stocks

ADMA vs RGEN

CABA vs RGEN

GILD vs RGEN
Winner: GILD

Create New Comparison

Tradestie